论文部分内容阅读
目的探讨布地奈德混悬液联合孟鲁斯特钠治疗小儿咳嗽变异性哮喘(CVA)的临床疗效。方法将82例临床诊断为CVA的患儿随机分为治疗组和对照组,各41例。对照组给予布地奈德混悬液雾化吸入,治疗组在对照组基础上加用孟鲁斯特钠,疗程均为12周,观察2组患儿咳嗽缓解时间,咳嗽消失时间,平均治疗时间,治疗前、后肺功能指标变化。结果 2组患儿治疗后临床症状明显改善,治疗组咳嗽缓解时间、咳嗽消失时间、平均治疗时间,均短于对照组,差异具有统计学意义(P<0.01)。两组治疗后肺功能指标FEV1,FEV1/FVC(%),PEF与治疗前比较,差异具有统计学意义(P<0.05),且治疗后肺功能指标FEV1,FEV1/FVC(%),PEF治疗组高于对照组,差异具有统计学意义(P<0.05)。结论布地奈德混悬液联合孟鲁斯特钠治疗CVA可明显改善患儿临床症状和肺功能,疗效确切,值得临床应用。
Objective To investigate the clinical efficacy of budesonide suspension combined with montelukast sodium in the treatment of children with cough variant asthma (CVA). Methods 82 cases of clinically diagnosed as CVA were randomly divided into treatment group and control group, 41 cases each. The control group was given budesonide suspension atomization inhalation, the treatment group in the control group based on the use of montelukast sodium, treatment were 12 weeks, two groups were observed cough relief time, cough disappear time, the average treatment time , Before and after treatment, changes in lung function indicators. Results The clinical symptoms of the two groups were significantly improved after treatment. The treatment group had shorter cough relief time, cough disappearance time and average treatment time than those in the control group (P <0.01). After treatment, FEV1, FEV1 / FVC (%) and PEF of the two groups after treatment were significantly different from those before treatment (P <0.05). After treatment, FEV1, FEV1 / FVC Group higher than the control group, the difference was statistically significant (P <0.05). Conclusions The combination of budesonide suspension and montelukast sodium in treatment of CVA can significantly improve the clinical symptoms and pulmonary function in children with definite curative effect and is worthy of clinical application.